Status:
ACTIVE_NOT_RECRUITING
Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients"
Lead Sponsor:
Mansoura University
Conditions:
Breast Cancer Female
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Breast cancer, a leading cause of cancer-related mortality in women worldwide, has spurred the investigation of novel therapeutic approaches. Pentoxifylline (PTX), a synthetic methylxanthine derivativ...
Eligibility Criteria
Inclusion
- Adult female patients \>18 years old with histologic confirmation of invasive breast cancer
- Planned to administer neoadjuvant chemotherapy protocol comprised of doxorubicin/ cyclophosphamide followed by paclitaxel (AC/T)
- Adequate hepatic, renal, and bone marrow functions
Exclusion
- Patients on treatment regimen of phosphodiesterase inhibitors
- Patients who are taking antiplatelet or anticoagulant treatment
- Patients who are allergic to phosphodiesterase inhibitors
- History of recent hemorrhagic events
- Active peptic ulcer
Key Trial Info
Start Date :
December 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2024
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06176339
Start Date
December 15 2023
End Date
September 30 2024
Last Update
March 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oncology center of Mansoura University
Al Mansurah, Egypt